0PQ Stock Chart & Stats
€1.50
€0.02(1.15%)
At close: 4:00 PM EDT
€1.50
€0.02(1.15%)
Day’s Range― - ―
52-Week Range€1.14 - €2.56
Previous CloseN/A
Volume0.00
Average Volume (3M)129.00
Market Cap
€276.51M
Enterprise Value€85.70
Total Cash (Recent Filing)€117.08M
Total Debt (Recent Filing)€13.19M
Price to Earnings (P/E)―
Beta1.47
Next Earnings
Nov 05, 2026EPS Estimate
-0.1Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.40
Shares Outstanding138,087,650
10 Day Avg. Volume295
30 Day Avg. Volume129
Financial Highlights & Ratios
PEG Ratio-0.38
Price to Book (P/B)3.12
Price to Sales (P/S)11.85
P/FCF Ratio-3.37
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€7.36Price Target Upside390.49% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-0.36
Revenue Forecast (FY)€13.44M
Bulls Say, Bears Say
Bulls Say
Axiomer Clinical ValidationFirst-in-human validation supports the scientific credibility of Axiomer and its mechanism. Sustained target engagement and favorable early safety may improve the platform’s ability to advance follow-on candidates and attract development partners.
Extended Cash RunwayThe financing materially extends operational capacity, allowing ProQR to fund clinical development and pursue milestones without an immediate need for additional capital. Greater liquidity improves negotiating flexibility with partners and supports sustained R&D execution.
Revenue And Gross-margin StrengthStrong revenue growth and high gross margins indicate that collaboration-related income can scale efficiently when programs generate payments. Although not yet sufficient for profitability, this economics profile provides operating leverage if partnerships and milestones expand.
Bears Say
Persistent Operating LossesThe company remains far from break-even despite improving revenue, meaning future value depends on successful clinical and partnering outcomes. Continued losses can erode equity and may limit strategic flexibility if development costs remain elevated.
Substantial Cash BurnNegative operating and free cash flow show that the business does not currently fund its research and clinical programs internally. Persistent burn increases dependence on financings, partnerships or milestone receipts and raises execution risk across the pipeline.
Financing And Development DependenceAs a clinical-stage biotech without established product sales, ProQR’s cash generation depends on partner funding, milestones and future approvals. This concentration makes financial progress sensitive to clinical results, partnership execution and potential shareholder dilution.
ProQR News
0PQ FAQ
What was ProQR’s price range in the past 12 months?
ProQR lowest stock price was €1.14 and its highest was €2.56 in the past 12 months.
What is ProQR’s market cap?
ProQR’s market cap is €276.51M.
When is ProQR’s upcoming earnings report date?
ProQR’s upcoming earnings report date is Nov 05, 2026 which is in 68 days.
How were ProQR’s earnings last quarter?
ProQR released its earnings results on Aug 13, 2026. The company reported -€0.08 earnings per share for the quarter, beating the consensus estimate of -€0.114 by €0.034.
Is ProQR overvalued?
According to Wall Street analysts ProQR’s price is currently Undervalued.
Does ProQR pay dividends?
ProQR does not currently pay dividends.
What is ProQR’s EPS estimate?
ProQR’s EPS estimate is -0.1.
How many shares outstanding does ProQR have?
ProQR has 138,087,650 shares outstanding.
What happened to ProQR’s price movement after its last earnings report?
ProQR reported an EPS of -€0.08 in its last earnings report, beating expectations of -€0.114. Following the earnings report the stock price went down -2.474%.
Which hedge fund is a major shareholder of ProQR?
Currently, no hedge funds are holding shares in DE:0PQ
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
ProQR Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€7.36 (390.49% Upside)
€7.36 (390.49% Upside)
Blogger Sentiment
Bullish
DE:0PQ Sentiment 100%
Sector Average 61%
Sector Average 61%
Insider Transactions
Bought Shares
Worth €925.3K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
-23.89%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-5.42%
Trailing 12-Months
Company Description
ProQR
ProQR Therapeutics N.V. operates as a biopharmaceutical enterprise dedicated to discovering and developing RNA-based therapies designed to address genetic disorders. The company's pipeline includes two primary drug candidates in advanced clinical stages: Sepofarsen is currently in a Phase II/III clinical trial, known as the ILLUMINATE trial, targeting Leber Congenital Amaurosis 10 (LCA10). Ultevursen is also undergoing Phase II/III evaluation for the treatment of USH2A-mediated retinitis pigmentosa and Usher syndrome. Beyond its clinical programs, ProQR is actively developing its proprietary Axiomer RNA base-editing platform technology. Strategic collaborations are central to ProQR's strategy, evidenced by its licensing agreements with institutions such as Radboud University Medical Center, Inserm Transfert SA, Ionis Pharmaceuticals, Inc., and Leiden University Medical Center. Furthermore, a significant license and research partnership exists with Eli Lilly and Company, focused on the discovery, advancement, and commercialization of novel medicines for genetic conditions impacting the liver and nervous system. Established in 2012, ProQR Therapeutics N.V. maintains its corporate headquarters in Leiden, the Netherlands.
0PQ Stock 12 Month Forecast
Average Price Target
€7.36
▲(390.49% Upside)
Technical Analysis
Codexis
―
Heron Therapeutics
―
Tiziana Life Sciences
―
Atea Pharmaceuticals
―
OmniAb
―